Arrowhead Pharmaceuticals has received authorisation from Health Canada for its siRNA medicine, Redemplo, for adults with FCS ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

A new study shows many doctors do not offer self-injected birth control, even though it is safe and effective.

Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

NICE has recommended natalizumab for adults with highly active RRMS, citing pregnancy suitability, biosimilar value and NHS ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

A study reveals that many clinicians remain unaware of self-administered injectable contraception, despite its decades-long availability. Self-administered injectable contraceptives have been an ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The ...

Health Canada has cleared the way for ALS patients in that nation to join the ongoing ALSTARS U.S. trial testing therapy ...